| scholarly article | Q13442814 |
| P356 | DOI | 10.3816/CBC.2010.N.023 |
| P698 | PubMed publication ID | 20299316 |
| P50 | author | Linda T Vahdat | Q40149511 |
| Javier Cortes | Q43114235 | ||
| Chris Twelves | Q47067174 | ||
| P2093 | author name string | Peter A Kaufman | |
| Jantien Wanders | |||
| Corina Akerele | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| metastatic breast cancer | Q12859063 | ||
| phase III clinical trial | Q42824827 | ||
| P304 | page(s) | 160-163 | |
| P577 | publication date | 2010-04-01 | |
| P1433 | published in | Clinical Breast Cancer | Q332245 |
| P1476 | title | Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer | |
| P478 | volume | 10 |
| Q37944440 | A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer |
| Q49261685 | Advances in the treatment of soft tissue sarcoma: focus on eribulin. |
| Q37788507 | Advances in therapy: eribulin improves survival for metastatic breast cancer |
| Q33609211 | Antiproliferative and Proapoptotic Activities of Marine Sponge Hyrtios erectus Extract on Breast Carcinoma Cell Line (MCF-7). |
| Q26865369 | Beyond taxanes: the next generation of microtubule-targeting agents |
| Q35995011 | Carcinomatous pericarditis in 3 breast cancer patients with long-term survival |
| Q35972102 | Cell death signaling and anticancer therapy |
| Q50117674 | Crambescidin 800, Isolated from the Marine Sponge Monanchora viridis, Induces Cell Cycle Arrest and Apoptosis in Triple-Negative Breast Cancer Cells |
| Q37928232 | Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future? |
| Q37279632 | Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea |
| Q47628083 | Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer. |
| Q37961957 | Emerging drugs in metastatic breast cancer: an update |
| Q37356090 | Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer |
| Q37637936 | Eribulin -- a review of preclinical and clinical studies. |
| Q36763961 | Eribulin for advanced breast cancer: a drug evaluation |
| Q28088354 | Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy |
| Q26774097 | Eribulin in the Management of Advanced Breast Cancer: Implications of Current Research Findings |
| Q35599745 | Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer |
| Q37745070 | Eribulin mesylate for the treatment of breast cancer. |
| Q37956659 | Eribulin mesylate for the treatment of late-stage breast cancer. |
| Q54694130 | Eribulin mesylate in breast cancer. |
| Q39257653 | Eribulin mesylate in heavily pretreated metastatic breast cancer patients: current practice in an Italian community hospital |
| Q35699382 | Eribulin mesylate in the treatment of metastatic breast cancer |
| Q43861920 | Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole |
| Q54626772 | Eribulin mesylate. |
| Q34031560 | Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer |
| Q39775442 | Eribulin mesylate: a promising new antineoplastic agent for locally advanced or metastatic breast cancer |
| Q41159925 | Eribulin shows high concentration and long retention in xenograft tumor tissues |
| Q38267039 | Eribulin: a new-generation antimicrotubule agent in lung cancer therapy |
| Q34485539 | Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients |
| Q38127449 | Finding chemo: the search for marine-based pharmaceutical drugs active against cancer |
| Q41588399 | Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer. |
| Q29618033 | Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy |
| Q39084613 | Long-term efficacy and safety of a third-line treatment with eribulin plus trastuzumab in a young breast cancer patient |
| Q35633623 | Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study |
| Q36629243 | Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin |
| Q54262056 | Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9. |
| Q35721526 | Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane |
| Q51091552 | Population pharmacometric analyses of eribulin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes |
| Q36095223 | Proposal for a novel methodology to screen and score cost versus survival for anticancer drugs in metastatic disease: could cost weigh in evaluation? |
| Q38016575 | Quality of life assessments in advanced breast cancer: should there be more consistency? |
| Q35578368 | Recently confirmed apoptosis-inducing lead compounds isolated from marine sponge of potential relevance in cancer treatment |
| Q46592179 | Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer. |
| Q37837738 | The medicinal potential of promising marine macrolides with anticancer activity |
| Q37958063 | The paradox of triple negative breast cancer: novel approaches to treatment |
| Q38424397 | Therapies for triple negative breast cancer |
| Q38086872 | Tubulin: an example of targeted chemotherapy |
| Q52335669 | [Search for natural substances with therapeutic activity: George R. Pettit]. |
Search more.